Accurate Mammogram Reading More Likely Following Mammotome Biopsy, Study Indicates

Publication
Article
OncologyONCOLOGY Vol 12 No 7
Volume 12
Issue 7

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual Multidisciplinary Symposium on Breast Disease in Amelia Island, Florida, a medical conference of radiologists and surgeons specializing in breast disease.

The study indicates that, compared to Mammotome biopsy, internal scarring from open surgical breast biopsy is more than twice as likely to influence the radiologist’s ability to read a subsequent mammogram. Researchers also found that open surgical biopsy caused nearly twice as much internal scarring as did Mammotome biopsy.

Scarring and Mammography

The study suggests that women who have open surgical biopsy are more likely to develop changes on future mammograms than are women who have had a Mammotome biopsy, said lead author Catherine A. Kusnick, MD, assistant professor of radiology at the University of Iowa College of Medicine. These changes may require additional mammographic evaluation on future mammograms.

Scarring from open surgical biopsy influenced the confidence level in reading mammograms in more than 72% of cases studied. In contrast, Mammotome biopsy influenced the confidence level in only 29.5% of cases studied.

"This is a significant improvement. Post biopsy scarring can sometimes mimic or mask subtle breast cancers. The reduced rate of scarring from Mammotome biopsy compared to surgical biopsy may make it easier for radiologists to read future mammograms," said Dr. Kusnick.

Researchers identified scarring on one-half of mammograms following open surgical biopsy, as compared with only 27.3% of mammograms following Mammotome biopsy.

The study involved five radiologists specializing in mammography but with different experience levels, who were blinded to biopsy technique, breast lesion location, and identifying features. The radiologists examined two sets of mammograms, 14 surgical and 19 Mammotome cases. Even with the relatively small number of cases, the methodology and findings indicate significant statistical accuracy for the study, Dr. Kusnick said.

Minimally Invasive

Mammotome biopsy allows women to have a quick, minimally invasive breast biopsy. During the half-hour, outpatient procedure, the physician inserts a sampling probe through a small nick in the patient’s breast, which does not have to be repeatedly removed and inserted. Following the biopsy, the patient goes home with a small adhesive strip to cover the skin nick.

Open surgical biopsy, by comparison, is a more costly, time-consuming process that requires anesthesia, an operating room, and sutures.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.